---
title: "OPM plans to issue shares to acquire 100% equity of Pengli Bio at a transaction price of 1.451 billion yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243322196.md"
description: "OPM plans to acquire 100% equity of Pengli Biotechnology from 31 counterparties through the issuance of shares and cash payment, with a transaction price of 1.451 billion yuan. This transaction will help the company introduce preclinical research client resources, expand the potential customer base, and enhance the early research and development pipeline, strengthening the commercialization prospects of innovative drugs"
datetime: "2025-06-05T16:49:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243322196.md)
  - [en](https://longbridge.com/en/news/243322196.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243322196.md)
---

# OPM plans to issue shares to acquire 100% equity of Pengli Bio at a transaction price of 1.451 billion yuan

According to the Zhitong Finance APP, OPM (688293.SH) disclosed the draft report on the issuance of shares and cash payment for asset acquisition and fundraising. The listed company plans to issue shares and pay cash to purchase 100% equity of Pengli Bio from 31 trading partners including PLHK, Jiaxing Huituo, Sequoia Hengchen, Gu Sheng Investment, TFPL, Hillhouse Chenjun, Hangzhou Tiger, Nantong Dongzheng, Jiangxi Jilin, CICC Qichen, Jiaxing Hetuo, Suzhou Chenling, Mifang Kangjian Venture Capital, Pingyang Guokai, Mifang Pharmaceutical Venture Capital, Wuhan Taiming, Shanghai Jingdu, Wang Guoan, Shanghai Yansheng, Hillhouse Qirui, Zhuhai Liangheng, Jiaxing Yuanlai, Shanghai Junpeng, Xiamen Yinglian, Shanghai Chengxi, Qingdao Qiandao, Shanghai Licheng, Suzhou Guofa, Qian Tingzhi, Shanghai Jingshu, and Shanghai Beiji Min. The transaction price is 1.451 billion yuan.

After the completion of this transaction, the listed company will introduce the target company's preclinical research customer resources, promoting the company's cell culture medium products and biopharmaceutical CDMO business to customers in the early stages of drug development, thereby expanding the company's potential customer base, increasing the number of early-stage research pipelines, and to some extent locking in innovative drug pipelines with good commercialization prospects, achieving a flow from front-end business to back-end business. At the same time, the listed company can also introduce its cell culture medium and CDMO cooperation customers into the target enterprise for preclinical efficacy research, forming complementary advantages in business between the two parties

### Related Stocks

- [688293.CN](https://longbridge.com/en/quote/688293.CN.md)

## Related News & Research

- [11:16 ETHaier ist die einzige IoT-Ökosystemmarke der Welt, die acht Jahre in Folge in die Kantar BrandZ Top 100 aufgenommen wurde](https://longbridge.com/en/news/286792596.md)
- [Cotton Falling Back to Start Turnaround Tuesday Trade](https://longbridge.com/en/news/286913130.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [The Kingfish Company Calls Extraordinary General Meeting in June 2026](https://longbridge.com/en/news/287170369.md)
- [12:23 ETGraceKennedy Foundation's 36th Annual Lecture to Highlight Progress in Restoring Kingston Harbour](https://longbridge.com/en/news/286798834.md)